Karolinska Development
An investment company that finances and supports innovative life science ventures.
KDEV | ST
Overview
Corporate Details
- ISIN(s):
- SE0002190850 (+1 more)
- LEI:
- 54930011ZA52NKO5W681
- Country:
- Sweden
- Address:
- Nanna Svartz väg 6A, 171 65 Solna
Description
Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2014-10-15 08:45 |
Bruno Lucidi appointed permanent CEO of Karolinska Development
|
English | 294.6 KB | ||
| 2014-10-15 08:45 |
Bruno Lucidi utnämnd till permanent VD för Karolinska Development
|
Swedish | 298.2 KB | ||
| 2014-09-30 08:47 |
Karolinska Development bjuder in till kapitalmarknadsdag och tidigarelägger rap…
|
Swedish | 280.6 KB | ||
| 2014-09-30 08:47 |
Karolinska Development invites to a Capital Markets Day and brings the third qu…
|
English | 279.0 KB | ||
| 2014-09-19 08:00 |
Umecrine Mood rapporterar positiva resultat från en explorativ fas I/II-studie …
|
Swedish | 311.7 KB | ||
| 2014-09-19 08:00 |
Umecrine Mood announces positive results from an exploratory Phase I/II study w…
|
English | 309.6 KB | ||
| 2014-08-21 08:00 | Swedish | 993.0 KB | |||
| 2014-08-21 08:00 | English | 997.3 KB | |||
| 2014-06-12 08:00 |
Umecrine Mood rapporterar preliminära data från en explorativ fas II-studie i p…
|
Swedish | 346.0 KB | ||
| 2014-06-12 08:00 |
Umecrine Mood reports preliminary data from exploratory Phase II study in preme…
|
English | 345.6 KB | ||
| 2014-05-30 08:00 |
Dilaforette AB presenterar resultat från explorativ fas I/II-studie i okomplice…
|
Swedish | 420.6 KB | ||
| 2014-05-30 08:00 |
Dilaforette presents results from exploratory Phase I/II clinical trial in unco…
|
English | 422.6 KB | ||
| 2014-05-15 08:30 |
Karolinska Developments årsstämma 2014
|
Swedish | 336.1 KB | ||
| 2014-05-15 08:30 |
Karolinska Development´s Annual General Meeting 2014
|
English | 337.3 KB | ||
| 2014-05-08 08:30 |
XSpray Announces Positive Phase I Data for HyNap™ Nilotinib
|
English | 344.6 KB |
Automate Your Workflow. Get a real-time feed of all Karolinska Development filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Karolinska Development
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Karolinska Development via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-04 | Johan Dighed | Other | Buy | 35,000 | 56,350.00 SEK |
| 2023-03-27 | Johan Dighed | Other | Buy | 50,000 | 89,000.00 SEK |
| 2023-02-17 | Hans Christopher Karl Osvald Perbandt Toll | Other | Buy | 35,000 | 72,100.00 SEK |
| 2022-12-19 | Johan Dighed | Other | Buy | 50,000 | 83,500.00 SEK |
| 2022-09-30 | Johan Dighed | Other | Buy | 40,187 | 72,336.60 SEK |
| 2020-06-26 | Hans Lennart Rudolf Wigzell | Other | Buy | 9,014 | 25,780.04 SEK |
| 2020-06-26 | Hans Lennart Rudolf Wigzell | Other | Buy | 5,000 | 14,350.00 SEK |
| 2020-06-24 | Hans Lennart Rudolf Wigzell | Other | Buy | 9,276 | 26,529.36 SEK |
| 2020-06-24 | Hans Lennart Rudolf Wigzell | Other | Buy | 4,645 | 13,331.15 SEK |
| 2020-06-23 | Hans Lennart Rudolf Wigzell | Other | Buy | 39,702 | 111,562.62 SEK |
Peer Companies
